Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

NAMSW NewAmsterdam Pharma Company NV

8,47

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 02:00:00

Verzögert um 15 Minuten

Form ARS - Annual Report to Security Holders

NewAmsterdam Pharma Comp... (NASDAQ:NAMSW)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more NewAmsterdam Pharma Comp... Charts.

NewAmsterdam Pharma Comp... (NASDAQ:NAMSW)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more NewAmsterdam Pharma Comp... Charts.

News NewAmsterdam Pharma Company NV

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
Dienstag 21 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Form ARS - Annual Report to Security Holders
Donnerstag 9 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Donnerstag 9 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Donnerstag 9 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 8 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freitag 3 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
Donnerstag 2 Mai 2024 (4 Wochen vor) • GlobeNewswire Inc.

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Dienstag 9 April 2024 (2 Monate vor) • GlobeNewswire Inc.

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Montag 1 April 2024 (2 Monate vor) • GlobeNewswire Inc.

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
Montag 25 März 2024 (2 Monate vor) • GlobeNewswire Inc.

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
Dienstag 12 März 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere NewAmsterdam Pharma Company NV News-Artikel

Hallenstein Glasson (PK)

Sonoco Products

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen